IMR Press / FBE / Volume 3 / Issue 2 / DOI: 10.2741/E257

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article

MYCN, neuroblastoma and focal adhesion kinase (FAK)

Show Less
1 1600 7th Avenue South, ACC, Room 300, University of Alabama, Birmingham, Birmingham, AL 35233

*Author to whom correspondence should be addressed,

 

Front. Biosci. (Elite Ed) 2011, 3(2), 421–433; https://doi.org/10.2741/E257
Published: 1 January 2011
Abstract

Neuroblastoma is the most common extracranial solid tumor of childhood. This tumor is characterized by poor survival, especially when it features amplification of the MYCN oncogene. The ability for human cancers to propagate is marked by their ability to invade and metastasize to distant sites. Focal adhesion kinase (FAK) is a key tyrosine kinase involved in the survival and metastasis of a number of human tumor types. We have shown that FAK is present in human neuroblastoma and that its expression in neuroblastoma is related to the MYCN oncogene. We have also demonstrated that inhibition of FAK in neuroblastoma leads to decreased tumor cell survival. The current review addresses the relationship between the MYCN oncogene, focal adhesion kinase and neuroblastoma.

Keywords
MYCN
neuroblastoma
FAK
Pediatric
SHEP-21/N
SK-N-AS
SK-N-BE(2)
Review
Share
Back to top